ArticleClinical rheumatology2026
Interferon-γ as a predictive biomarker for macrophage activation syndrome in systemic JIA: a chinese multicenter study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectivesTo develop and validate interferon-γ-based early prediction models for MAS in pediatric SJIA patients.
methodsWe conducted a retrospective multicentre study of hospitalized SJIA patients complicated with MAS across seven tertiary paediatric centres in China between January 2020 and December 2024. Demographic, clinical, laboratory, and cytokine data were extracted from electronic medical records. Univariate and multivariate logistic regression analyses identified independent risk factors. A nomogram and cytokine-based predictive models were constructed and externally validated.
resultsIn the training cohort, independent predictors of MAS included thrombocytopenia (≤ 181 × 10⁹/L; OR 31.5, P = 0.002), elevated AST (> 50 U/L; OR 24.5, P < 0.001), hypertriglyceridaemia (> 1.76 mmol/L; OR 12.0, P < 0.001), hyperferritinaemia (> 684 μg/L; OR 33.0, P < 0.001), hypofibrinogenaemia (≤ 3.6 g/L; OR 24.9, P < 0.001), elevated D-dimer (> 5.0 mg/L; OR 26.3, P < 0.001), increased IL-10 (> 15 pg/mL; OR 29.4, P < 0.001), and IFN-γ (≥ 20 pg/mL; OR 17.9, P < 0.001). A clinical nomogram incorporating AST, fibrinogen, and ferritin yielded an area under the curve (AUC) of 0.92 for MAS prediction. Furthermore, integrating IFN-γwith specific clinical marker (AST, and fibrinogen, or ferritin and fibrinogen) established enhanced models that maintained robust discriminative accuracy across training and external validation cohorts. with AUCs ranging from 0.91 to 0.98.
conclusionWe developed and validated early prediction tools for MAS in paediatric SJIA by integrating serum IFN-γ with clinical parameters. These models may support timely diagnosis and treatment. Key points • Serum IFN-γ is a strong early biomarker for MAS in SJIA. • A cytokine-enhanced model improves MAS risk prediction in paediatric SJIA. • Ferritin, AST, and fibrinogen remain core predictors of MAS.
Indexed as
Identifiers
42823549What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.